{"entity":{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","aka":["PANCONVA"],"tldr":"A phase 1/2 trial of onvansertib and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by University of Kansas Medical Center, now recruiting.","summary":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06736717 by University of Kansas Medical Center, with a registry enrolment figure of 21 participants, started 2025-02 and due to reach its primary completion in 2026-07. Interventions recorded: Onvansertib; NALIRIFOX. Conditions listed: Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR). Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06736717","url":"https://clinicaltrials.gov/study/NCT06736717"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["onvansertib","nalirifox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06736717","phase":"1/2","setting":"A Phase 1b/2 Trial of Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","sponsor":"University of Kansas Medical Center","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06736717/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/"},{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}